nodes	percent_of_prediction	percent_of_DWPC	metapath
Alitretinoin—Acitretin—psoriasis	0.249	1	CrCtD
Alitretinoin—Retinoids—Tazarotene—psoriasis	0.164	0.5	CiPCiCtD
Alitretinoin—Retinoids—Acitretin—psoriasis	0.164	0.5	CiPCiCtD
Alitretinoin—Isotretinoin—Acitretin—psoriasis	0.0533	0.333	CrCrCtD
Alitretinoin—Vitamin A—Acitretin—psoriasis	0.0533	0.333	CrCrCtD
Alitretinoin—Tretinoin—Acitretin—psoriasis	0.0533	0.333	CrCrCtD
Alitretinoin—RARG—Tazarotene—psoriasis	0.0241	0.121	CbGbCtD
Alitretinoin—RXRB—Tazarotene—psoriasis	0.0213	0.107	CbGbCtD
Alitretinoin—RARB—Tazarotene—psoriasis	0.0213	0.107	CbGbCtD
Alitretinoin—RARA—Tazarotene—psoriasis	0.0213	0.107	CbGbCtD
Alitretinoin—RXRG—Acitretin—psoriasis	0.019	0.096	CbGbCtD
Alitretinoin—RARG—Acitretin—psoriasis	0.019	0.096	CbGbCtD
Alitretinoin—RARB—Acitretin—psoriasis	0.0168	0.0849	CbGbCtD
Alitretinoin—RARA—Acitretin—psoriasis	0.0168	0.0849	CbGbCtD
Alitretinoin—RXRB—Acitretin—psoriasis	0.0168	0.0849	CbGbCtD
Alitretinoin—RXRA—Acitretin—psoriasis	0.0168	0.0849	CbGbCtD
Alitretinoin—CYP1A2—Clobetasol propionate—psoriasis	0.0016	0.00806	CbGbCtD
Alitretinoin—CRABP2—skin epidermis—psoriasis	0.000915	0.301	CbGeAlD
Alitretinoin—CYP1A2—Methoxsalen—psoriasis	0.000838	0.00423	CbGbCtD
Alitretinoin—ABCB1—Mycophenolate mofetil—psoriasis	0.000421	0.00213	CbGbCtD
Alitretinoin—ABCB1—Betamethasone—psoriasis	0.000361	0.00182	CbGbCtD
Alitretinoin—ABCB1—Prednisolone—psoriasis	0.000356	0.0018	CbGbCtD
Alitretinoin—ABCB1—Hydrocortisone—psoriasis	0.000338	0.00171	CbGbCtD
Alitretinoin—ABCB1—Prednisone—psoriasis	0.000337	0.0017	CbGbCtD
Alitretinoin—ABCB1—Cyclosporine—psoriasis	0.000319	0.00161	CbGbCtD
Alitretinoin—CRABP1—skin of body—psoriasis	0.000313	0.103	CbGeAlD
Alitretinoin—CRABP2—skin of body—psoriasis	0.000283	0.0933	CbGeAlD
Alitretinoin—CRABP1—tendon—psoriasis	0.000239	0.0786	CbGeAlD
Alitretinoin—CRABP2—tendon—psoriasis	0.000216	0.071	CbGeAlD
Alitretinoin—ABCB1—Dexamethasone—psoriasis	0.00021	0.00106	CbGbCtD
Alitretinoin—RARG—skin of body—psoriasis	0.000207	0.0681	CbGeAlD
Alitretinoin—RARB—tendon—psoriasis	0.000193	0.0635	CbGeAlD
Alitretinoin—RXRG—tendon—psoriasis	0.000189	0.0621	CbGeAlD
Alitretinoin—RXRB—tendon—psoriasis	0.000177	0.0584	CbGeAlD
Alitretinoin—ABCB1—Methotrexate—psoriasis	0.000169	0.000853	CbGbCtD
Alitretinoin—RARG—tendon—psoriasis	0.000157	0.0518	CbGeAlD
Alitretinoin—RARA—tendon—psoriasis	0.000148	0.0487	CbGeAlD
Alitretinoin—RXRA—Activation of gene expression by SREBF (SREBP)—CARM1—psoriasis	0.000106	0.00765	CbGpPWpGaD
Alitretinoin—CRABP1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000105	0.00759	CbGpPWpGaD
Alitretinoin—CRABP2—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000105	0.00759	CbGpPWpGaD
Alitretinoin—RARB—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000104	0.00753	CbGpPWpGaD
Alitretinoin—RARG—Nuclear Receptors—PPARG—psoriasis	0.000102	0.00741	CbGpPWpGaD
Alitretinoin—RARB—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.0001	0.00726	CbGpPWpGaD
Alitretinoin—RARA—Nuclear Receptor transcription pathway—VDR—psoriasis	9.97e-05	0.00722	CbGpPWpGaD
Alitretinoin—RXRB—Nuclear Receptor transcription pathway—VDR—psoriasis	9.97e-05	0.00722	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional activation of mitochondrial biogenesis—CARM1—psoriasis	9.62e-05	0.00696	CbGpPWpGaD
Alitretinoin—RARA—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.61e-05	0.00696	CbGpPWpGaD
Alitretinoin—RXRG—Nuclear Receptors—PPARG—psoriasis	9.35e-05	0.00677	CbGpPWpGaD
Alitretinoin—RARB—Nuclear Receptors—PPARG—psoriasis	9.17e-05	0.00664	CbGpPWpGaD
Alitretinoin—RXRA—The citric acid (TCA) cycle and respiratory electron transport—NDUFA5—psoriasis	8.98e-05	0.00651	CbGpPWpGaD
Alitretinoin—RXRA—RXR and RAR heterodimerization with other nuclear receptor—VDR—psoriasis	8.91e-05	0.00645	CbGpPWpGaD
Alitretinoin—RARA—Nuclear Receptors—PPARG—psoriasis	8.79e-05	0.00637	CbGpPWpGaD
Alitretinoin—RXRB—Nuclear Receptors—PPARG—psoriasis	8.79e-05	0.00637	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of Androgen receptor activity—REL—psoriasis	8.56e-05	0.0062	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of Androgen receptor activity—CARM1—psoriasis	8.44e-05	0.00611	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of cholesterol biosynthesis by SREBP (SREBF)—CARM1—psoriasis	8.44e-05	0.00611	CbGpPWpGaD
Alitretinoin—RXRA—Mitochondrial biogenesis—CARM1—psoriasis	8.31e-05	0.00602	CbGpPWpGaD
Alitretinoin—RXRA—Circadian Clock—CARM1—psoriasis	8.19e-05	0.00593	CbGpPWpGaD
Alitretinoin—RXRA—Transcription factor regulation in adipogenesis—LEP—psoriasis	8.15e-05	0.0059	CbGpPWpGaD
Alitretinoin—RARG—Nuclear Receptor transcription pathway—PPARG—psoriasis	8.08e-05	0.00585	CbGpPWpGaD
Alitretinoin—RXRA—Retinoic acid receptors-mediated signaling—VDR—psoriasis	7.94e-05	0.00575	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.87e-05	0.0057	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	7.55e-05	0.00547	CbGpPWpGaD
Alitretinoin—RXRG—Nuclear Receptor transcription pathway—PPARG—psoriasis	7.39e-05	0.00535	CbGpPWpGaD
Alitretinoin—RARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	7.36e-05	0.00533	CbGpPWpGaD
Alitretinoin—RARB—Nuclear Receptor transcription pathway—PPARG—psoriasis	7.25e-05	0.00525	CbGpPWpGaD
Alitretinoin—RXRA—Transcription factor regulation in adipogenesis—PPARG—psoriasis	7.1e-05	0.00514	CbGpPWpGaD
Alitretinoin—RARA—Nuclear Receptor transcription pathway—PPARG—psoriasis	6.95e-05	0.00503	CbGpPWpGaD
Alitretinoin—RXRB—Nuclear Receptor transcription pathway—PPARG—psoriasis	6.95e-05	0.00503	CbGpPWpGaD
Alitretinoin—RXRA—Biological oxidations—CYP2S1—psoriasis	6.74e-05	0.00488	CbGpPWpGaD
Alitretinoin—RXRG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	6.73e-05	0.00487	CbGpPWpGaD
Alitretinoin—RARB—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	6.6e-05	0.00478	CbGpPWpGaD
Alitretinoin—RXRA—Nuclear Receptors—VDR—psoriasis	6.57e-05	0.00476	CbGpPWpGaD
Alitretinoin—RARA—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	6.33e-05	0.00458	CbGpPWpGaD
Alitretinoin—RXRB—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	6.33e-05	0.00458	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	6.26e-05	0.00453	CbGpPWpGaD
Alitretinoin—RXRA—RXR and RAR heterodimerization with other nuclear receptor—PPARG—psoriasis	6.21e-05	0.0045	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—SOCS1—psoriasis	5.44e-05	0.00394	CbGpPWpGaD
Alitretinoin—RXRA—Nuclear Receptor transcription pathway—VDR—psoriasis	5.19e-05	0.00376	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—TARS—psoriasis	5.13e-05	0.00372	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—SOCS1—psoriasis	5.11e-05	0.0037	CbGpPWpGaD
Alitretinoin—RXRG—Regulation of Androgen receptor activity—JUN—psoriasis	5.08e-05	0.00368	CbGpPWpGaD
Alitretinoin—ABCB1—Drug Induction of Bile Acid Pathway—VDR—psoriasis	5e-05	0.00362	CbGpPWpGaD
Alitretinoin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	4.99e-05	0.00361	CbGpPWpGaD
Alitretinoin—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	4.92e-05	0.00357	CbGpPWpGaD
Alitretinoin—RXRA—Orphan transporters—CARM1—psoriasis	4.92e-05	0.00356	CbGpPWpGaD
Alitretinoin—RXRB—Regulation of Androgen receptor activity—JUN—psoriasis	4.78e-05	0.00346	CbGpPWpGaD
Alitretinoin—RXRA—PPARA activates gene expression—CARM1—psoriasis	4.7e-05	0.00341	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—TARS—psoriasis	4.69e-05	0.0034	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	4.6e-05	0.00333	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—TARS—psoriasis	4.6e-05	0.00333	CbGpPWpGaD
Alitretinoin—RXRA—Nuclear Receptors—PPARG—psoriasis	4.58e-05	0.00332	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—NDUFA5—psoriasis	4.48e-05	0.00324	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—NDUFA5—psoriasis	4.48e-05	0.00324	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—TARS—psoriasis	4.41e-05	0.00319	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—TARS—psoriasis	4.41e-05	0.00319	CbGpPWpGaD
Alitretinoin—CRABP2—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	4.36e-05	0.00316	CbGpPWpGaD
Alitretinoin—CRABP1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	4.36e-05	0.00316	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.17e-05	0.00302	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.17e-05	0.00302	CbGpPWpGaD
Alitretinoin—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	4.05e-05	0.00293	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—LEP—psoriasis	4.01e-05	0.00291	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	3.93e-05	0.00285	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—CYP2S1—psoriasis	3.81e-05	0.00276	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—CYP2S1—psoriasis	3.81e-05	0.00276	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—LEP—psoriasis	3.77e-05	0.00273	CbGpPWpGaD
Alitretinoin—RXRA—Organelle biogenesis and maintenance—CARM1—psoriasis	3.77e-05	0.00273	CbGpPWpGaD
Alitretinoin—RXRA—Transcription factor regulation in adipogenesis—TNF—psoriasis	3.77e-05	0.00273	CbGpPWpGaD
Alitretinoin—RXRA—NRF2 pathway—TGFA—psoriasis	3.75e-05	0.00272	CbGpPWpGaD
Alitretinoin—RXRA—Nuclear Receptor transcription pathway—PPARG—psoriasis	3.62e-05	0.00262	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—PPARG—psoriasis	3.5e-05	0.00253	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—CARM1—psoriasis	3.35e-05	0.00243	CbGpPWpGaD
Alitretinoin—RXRA—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	3.3e-05	0.00239	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—PPARG—psoriasis	3.29e-05	0.00238	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.21e-05	0.00232	CbGpPWpGaD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	3.17e-05	0.0023	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	3.08e-05	0.00223	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—CARM1—psoriasis	3.07e-05	0.00222	CbGpPWpGaD
Alitretinoin—RXRA—Transcription factor regulation in adipogenesis—IL6—psoriasis	3.04e-05	0.0022	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—CARM1—psoriasis	3.01e-05	0.00218	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	2.99e-05	0.00217	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—CP—psoriasis	2.97e-05	0.00215	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—CARM1—psoriasis	2.88e-05	0.00209	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—CARM1—psoriasis	2.88e-05	0.00209	CbGpPWpGaD
Alitretinoin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	2.87e-05	0.00208	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.7e-05	0.00195	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—SOCS1—psoriasis	2.67e-05	0.00193	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—PPARG—psoriasis	2.6e-05	0.00189	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.59e-05	0.00187	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of Androgen receptor activity—JUN—psoriasis	2.49e-05	0.0018	CbGpPWpGaD
Alitretinoin—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	2.45e-05	0.00177	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	2.39e-05	0.00173	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—TARS—psoriasis	2.3e-05	0.00167	CbGpPWpGaD
Alitretinoin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	2.29e-05	0.00166	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—HLA-C—psoriasis	2.29e-05	0.00166	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IL13—psoriasis	2.27e-05	0.00165	CbGpPWpGaD
Alitretinoin—CYP1A2—Biological oxidations—CYP2S1—psoriasis	2.15e-05	0.00156	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—STAT3—psoriasis	2.15e-05	0.00155	CbGpPWpGaD
Alitretinoin—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	2.12e-05	0.00154	CbGpPWpGaD
Alitretinoin—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	2.12e-05	0.00153	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IL17A—psoriasis	2.09e-05	0.00152	CbGpPWpGaD
Alitretinoin—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	2.08e-05	0.00151	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—STAT3—psoriasis	2.02e-05	0.00146	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—VDR—psoriasis	2e-05	0.00145	CbGpPWpGaD
Alitretinoin—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	2e-05	0.00145	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.99e-05	0.00144	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.99e-05	0.00144	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—LEP—psoriasis	1.97e-05	0.00142	CbGpPWpGaD
Alitretinoin—RXRA—PPARA activates gene expression—PPARG—psoriasis	1.96e-05	0.00142	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IL12B—psoriasis	1.95e-05	0.00141	CbGpPWpGaD
Alitretinoin—RXRA—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	1.92e-05	0.00139	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—HLA-E—psoriasis	1.9e-05	0.00138	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—CARM1—psoriasis	1.86e-05	0.00135	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—CARM1—psoriasis	1.86e-05	0.00135	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—TNF—psoriasis	1.86e-05	0.00134	CbGpPWpGaD
Alitretinoin—CYP1A2—Tryptophan metabolism—CAT—psoriasis	1.85e-05	0.00134	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—VDR—psoriasis	1.83e-05	0.00133	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—VDR—psoriasis	1.8e-05	0.0013	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.79e-05	0.00129	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	1.78e-05	0.00129	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—TNF—psoriasis	1.75e-05	0.00126	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.74e-05	0.00126	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.74e-05	0.00126	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—VDR—psoriasis	1.72e-05	0.00125	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—VDR—psoriasis	1.72e-05	0.00125	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.72e-05	0.00125	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.71e-05	0.00124	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—PPARG—psoriasis	1.71e-05	0.00124	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.65e-05	0.00119	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—CARM1—psoriasis	1.61e-05	0.00117	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	1.6e-05	0.00116	CbGpPWpGaD
Alitretinoin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	1.6e-05	0.00116	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	1.57e-05	0.00114	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.56e-05	0.00113	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—CARM1—psoriasis	1.5e-05	0.00109	CbGpPWpGaD
Alitretinoin—RXRG—Adipogenesis—IL6—psoriasis	1.5e-05	0.00109	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.5e-05	0.00108	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—CARM1—psoriasis	1.48e-05	0.00107	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—CARM1—psoriasis	1.45e-05	0.00105	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IL10—psoriasis	1.42e-05	0.00103	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—CARM1—psoriasis	1.41e-05	0.00102	CbGpPWpGaD
Alitretinoin—RARA—Adipogenesis—IL6—psoriasis	1.41e-05	0.00102	CbGpPWpGaD
Alitretinoin—RARG—Generic Transcription Pathway—PPARG—psoriasis	1.4e-05	0.00101	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—CARM1—psoriasis	1.39e-05	0.00101	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—CARM1—psoriasis	1.39e-05	0.00101	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IL4—psoriasis	1.38e-05	0.001	CbGpPWpGaD
Alitretinoin—RXRA—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	1.38e-05	0.001	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—NDUFA5—psoriasis	1.35e-05	0.000981	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—HLA-B—psoriasis	1.35e-05	0.00098	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	1.35e-05	0.000979	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	1.35e-05	0.000976	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.34e-05	0.000969	CbGpPWpGaD
Alitretinoin—RXRA—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	1.32e-05	0.000956	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.28e-05	0.000929	CbGpPWpGaD
Alitretinoin—RXRG—Generic Transcription Pathway—PPARG—psoriasis	1.28e-05	0.000925	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.26e-05	0.000915	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	1.26e-05	0.000912	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—CP—psoriasis	1.26e-05	0.000912	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—HLA-A—psoriasis	1.25e-05	0.000908	CbGpPWpGaD
Alitretinoin—RARB—Generic Transcription Pathway—PPARG—psoriasis	1.25e-05	0.000907	CbGpPWpGaD
Alitretinoin—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	1.24e-05	0.000897	CbGpPWpGaD
Alitretinoin—RXRA—Transmembrane transport of small molecules—CARM1—psoriasis	1.2e-05	0.00087	CbGpPWpGaD
Alitretinoin—RARA—Generic Transcription Pathway—PPARG—psoriasis	1.2e-05	0.000869	CbGpPWpGaD
Alitretinoin—RXRB—Generic Transcription Pathway—PPARG—psoriasis	1.2e-05	0.000869	CbGpPWpGaD
Alitretinoin—RARB—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.18e-05	0.000855	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CYP2S1—psoriasis	1.15e-05	0.000834	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	1.15e-05	0.00083	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—CAT—psoriasis	1.14e-05	0.000828	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—CAT—psoriasis	1.14e-05	0.000828	CbGpPWpGaD
Alitretinoin—RARA—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.13e-05	0.000819	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—STAT3—psoriasis	1.05e-05	0.000761	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	1.03e-05	0.000746	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—VDR—psoriasis	9.64e-06	0.000698	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—TNF—psoriasis	9.1e-06	0.000659	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—VDR—psoriasis	8.97e-06	0.00065	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	8.93e-06	0.000647	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	8.9e-06	0.000645	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—APOE—psoriasis	8.88e-06	0.000643	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—APOE—psoriasis	8.88e-06	0.000643	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—VDR—psoriasis	8.82e-06	0.000639	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—VDR—psoriasis	8.65e-06	0.000626	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	8.6e-06	0.000623	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	8.57e-06	0.00062	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—IFNG—psoriasis	8.37e-06	0.000606	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	8.35e-06	0.000605	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—VDR—psoriasis	8.29e-06	0.0006	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—VDR—psoriasis	8.29e-06	0.0006	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	7.8e-06	0.000565	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—CXCL8—psoriasis	7.78e-06	0.000563	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	7.78e-06	0.000563	CbGpPWpGaD
Alitretinoin—CRABP1—Metabolism—PPARG—psoriasis	7.74e-06	0.00056	CbGpPWpGaD
Alitretinoin—CRABP2—Metabolism—PPARG—psoriasis	7.74e-06	0.00056	CbGpPWpGaD
Alitretinoin—RXRA—Adipogenesis—IL6—psoriasis	7.34e-06	0.000532	CbGpPWpGaD
Alitretinoin—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	7.3e-06	0.000528	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—CARM1—psoriasis	7.24e-06	0.000524	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—LEP—psoriasis	6.76e-06	0.00049	CbGpPWpGaD
Alitretinoin—RARG—Gene Expression—PPARG—psoriasis	6.72e-06	0.000487	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.69e-06	0.000484	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	6.66e-06	0.000483	CbGpPWpGaD
Alitretinoin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	6.66e-06	0.000483	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	6.41e-06	0.000464	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—VEGFA—psoriasis	6.32e-06	0.000458	CbGpPWpGaD
Alitretinoin—RXRA—Generic Transcription Pathway—PPARG—psoriasis	6.26e-06	0.000453	CbGpPWpGaD
Alitretinoin—RXRG—Gene Expression—PPARG—psoriasis	6.15e-06	0.000445	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.04e-06	0.000437	CbGpPWpGaD
Alitretinoin—RARB—Gene Expression—PPARG—psoriasis	6.03e-06	0.000437	CbGpPWpGaD
Alitretinoin—RXRA—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.9e-06	0.000427	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—PPARG—psoriasis	5.89e-06	0.000426	CbGpPWpGaD
Alitretinoin—RXRB—Gene Expression—PPARG—psoriasis	5.78e-06	0.000419	CbGpPWpGaD
Alitretinoin—RARA—Gene Expression—PPARG—psoriasis	5.78e-06	0.000419	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—CARM1—psoriasis	5.63e-06	0.000407	CbGpPWpGaD
Alitretinoin—ABCB1—Allograft Rejection—TNF—psoriasis	5.42e-06	0.000392	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—NDUFA5—psoriasis	5.41e-06	0.000392	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	5.38e-06	0.00039	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.26e-06	0.000381	CbGpPWpGaD
Alitretinoin—RXRA—Developmental Biology—TYK2—psoriasis	5.16e-06	0.000374	CbGpPWpGaD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	5.03e-06	0.000364	CbGpPWpGaD
Alitretinoin—Anxiety—Dexamethasone—psoriasis	4.85e-06	0.000101	CcSEcCtD
Alitretinoin—Vomiting—Mycophenolic acid—psoriasis	4.83e-06	0.000101	CcSEcCtD
Alitretinoin—Discomfort—Betamethasone—psoriasis	4.81e-06	0.0001	CcSEcCtD
Alitretinoin—Discomfort—Dexamethasone—psoriasis	4.81e-06	0.0001	CcSEcCtD
Alitretinoin—Dyspepsia—Hydrocortisone—psoriasis	4.81e-06	0.0001	CcSEcCtD
Alitretinoin—Haemoglobin—Methotrexate—psoriasis	4.8e-06	0.0001	CcSEcCtD
Alitretinoin—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	4.8e-06	0.000348	CbGpPWpGaD
Alitretinoin—Rash—Mycophenolic acid—psoriasis	4.79e-06	0.0001	CcSEcCtD
Alitretinoin—Dermatitis—Mycophenolic acid—psoriasis	4.78e-06	9.99e-05	CcSEcCtD
Alitretinoin—Pain—Prednisolone—psoriasis	4.78e-06	9.98e-05	CcSEcCtD
Alitretinoin—Hepatitis—Methotrexate—psoriasis	4.78e-06	9.98e-05	CcSEcCtD
Alitretinoin—Haemorrhage—Methotrexate—psoriasis	4.78e-06	9.98e-05	CcSEcCtD
Alitretinoin—Urticaria—Mycophenolate mofetil—psoriasis	4.76e-06	9.94e-05	CcSEcCtD
Alitretinoin—Headache—Mycophenolic acid—psoriasis	4.76e-06	9.93e-05	CcSEcCtD
Alitretinoin—Decreased appetite—Hydrocortisone—psoriasis	4.75e-06	9.91e-05	CcSEcCtD
Alitretinoin—Pharyngitis—Methotrexate—psoriasis	4.74e-06	9.9e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Mycophenolate mofetil—psoriasis	4.74e-06	9.89e-05	CcSEcCtD
Alitretinoin—Abdominal pain—Mycophenolate mofetil—psoriasis	4.74e-06	9.89e-05	CcSEcCtD
Alitretinoin—Urinary tract disorder—Methotrexate—psoriasis	4.72e-06	9.85e-05	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.71e-06	9.84e-05	CcSEcCtD
Alitretinoin—Fatigue—Hydrocortisone—psoriasis	4.71e-06	9.83e-05	CcSEcCtD
Alitretinoin—Vision blurred—Prednisone—psoriasis	4.69e-06	9.8e-05	CcSEcCtD
Alitretinoin—Urethral disorder—Methotrexate—psoriasis	4.68e-06	9.78e-05	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.68e-06	9.78e-05	CcSEcCtD
Alitretinoin—Pain—Hydrocortisone—psoriasis	4.67e-06	9.75e-05	CcSEcCtD
Alitretinoin—Anaphylactic shock—Dexamethasone—psoriasis	4.67e-06	9.74e-05	CcSEcCtD
Alitretinoin—Oedema—Dexamethasone—psoriasis	4.67e-06	9.74e-05	CcSEcCtD
Alitretinoin—Oedema—Betamethasone—psoriasis	4.67e-06	9.74e-05	CcSEcCtD
Alitretinoin—Anaphylactic shock—Betamethasone—psoriasis	4.67e-06	9.74e-05	CcSEcCtD
Alitretinoin—Insomnia—Triamcinolone—psoriasis	4.65e-06	9.71e-05	CcSEcCtD
Alitretinoin—Infection—Dexamethasone—psoriasis	4.63e-06	9.68e-05	CcSEcCtD
Alitretinoin—Infection—Betamethasone—psoriasis	4.63e-06	9.68e-05	CcSEcCtD
Alitretinoin—Ill-defined disorder—Prednisone—psoriasis	4.62e-06	9.64e-05	CcSEcCtD
Alitretinoin—Paraesthesia—Triamcinolone—psoriasis	4.62e-06	9.64e-05	CcSEcCtD
Alitretinoin—Feeling abnormal—Prednisolone—psoriasis	4.61e-06	9.62e-05	CcSEcCtD
Alitretinoin—Visual impairment—Methotrexate—psoriasis	4.61e-06	9.62e-05	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—CYP2S1—psoriasis	4.6e-06	0.000333	CbGpPWpGaD
Alitretinoin—Anaemia—Prednisone—psoriasis	4.6e-06	9.61e-05	CcSEcCtD
Alitretinoin—Shock—Betamethasone—psoriasis	4.59e-06	9.58e-05	CcSEcCtD
Alitretinoin—Shock—Dexamethasone—psoriasis	4.59e-06	9.58e-05	CcSEcCtD
Alitretinoin—Dyspnoea—Triamcinolone—psoriasis	4.58e-06	9.57e-05	CcSEcCtD
Alitretinoin—Nervous system disorder—Dexamethasone—psoriasis	4.58e-06	9.55e-05	CcSEcCtD
Alitretinoin—Nervous system disorder—Betamethasone—psoriasis	4.58e-06	9.55e-05	CcSEcCtD
Alitretinoin—Agitation—Prednisone—psoriasis	4.57e-06	9.55e-05	CcSEcCtD
Alitretinoin—Thrombocytopenia—Betamethasone—psoriasis	4.57e-06	9.54e-05	CcSEcCtD
Alitretinoin—Thrombocytopenia—Dexamethasone—psoriasis	4.57e-06	9.54e-05	CcSEcCtD
Alitretinoin—Tachycardia—Betamethasone—psoriasis	4.55e-06	9.51e-05	CcSEcCtD
Alitretinoin—Tachycardia—Dexamethasone—psoriasis	4.55e-06	9.51e-05	CcSEcCtD
Alitretinoin—Hypersensitivity—Cyclosporine—psoriasis	4.53e-06	9.45e-05	CcSEcCtD
Alitretinoin—Dyspepsia—Triamcinolone—psoriasis	4.53e-06	9.45e-05	CcSEcCtD
Alitretinoin—Erythema multiforme—Methotrexate—psoriasis	4.52e-06	9.43e-05	CcSEcCtD
Alitretinoin—Nausea—Mycophenolic acid—psoriasis	4.51e-06	9.42e-05	CcSEcCtD
Alitretinoin—Hyperhidrosis—Dexamethasone—psoriasis	4.51e-06	9.42e-05	CcSEcCtD
Alitretinoin—Hyperhidrosis—Betamethasone—psoriasis	4.51e-06	9.42e-05	CcSEcCtD
Alitretinoin—Feeling abnormal—Hydrocortisone—psoriasis	4.5e-06	9.39e-05	CcSEcCtD
Alitretinoin—Malaise—Prednisone—psoriasis	4.49e-06	9.37e-05	CcSEcCtD
Alitretinoin—Eye disorder—Methotrexate—psoriasis	4.47e-06	9.32e-05	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Hydrocortisone—psoriasis	4.47e-06	9.32e-05	CcSEcCtD
Alitretinoin—Syncope—Prednisone—psoriasis	4.46e-06	9.32e-05	CcSEcCtD
Alitretinoin—Tinnitus—Methotrexate—psoriasis	4.46e-06	9.3e-05	CcSEcCtD
Alitretinoin—Anorexia—Dexamethasone—psoriasis	4.45e-06	9.28e-05	CcSEcCtD
Alitretinoin—Anorexia—Betamethasone—psoriasis	4.45e-06	9.28e-05	CcSEcCtD
Alitretinoin—Urticaria—Prednisolone—psoriasis	4.44e-06	9.27e-05	CcSEcCtD
Alitretinoin—Fatigue—Triamcinolone—psoriasis	4.43e-06	9.26e-05	CcSEcCtD
Alitretinoin—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.42e-06	9.22e-05	CcSEcCtD
Alitretinoin—Asthenia—Cyclosporine—psoriasis	4.41e-06	9.2e-05	CcSEcCtD
Alitretinoin—Pain—Triamcinolone—psoriasis	4.4e-06	9.18e-05	CcSEcCtD
Alitretinoin—Loss of consciousness—Prednisone—psoriasis	4.38e-06	9.14e-05	CcSEcCtD
Alitretinoin—Hypotension—Betamethasone—psoriasis	4.36e-06	9.1e-05	CcSEcCtD
Alitretinoin—Hypotension—Dexamethasone—psoriasis	4.36e-06	9.1e-05	CcSEcCtD
Alitretinoin—Pruritus—Cyclosporine—psoriasis	4.35e-06	9.08e-05	CcSEcCtD
Alitretinoin—Urticaria—Hydrocortisone—psoriasis	4.34e-06	9.06e-05	CcSEcCtD
Alitretinoin—Angiopathy—Methotrexate—psoriasis	4.34e-06	9.05e-05	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism—NDUFA5—psoriasis	4.32e-06	0.000313	CbGpPWpGaD
Alitretinoin—RXRA—Gene Expression—VDR—psoriasis	4.32e-06	0.000313	CbGpPWpGaD
Alitretinoin—Abdominal pain—Hydrocortisone—psoriasis	4.32e-06	9.01e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Hydrocortisone—psoriasis	4.32e-06	9.01e-05	CcSEcCtD
Alitretinoin—Convulsion—Prednisone—psoriasis	4.31e-06	9.01e-05	CcSEcCtD
Alitretinoin—Asthenia—Mycophenolate mofetil—psoriasis	4.3e-06	8.98e-05	CcSEcCtD
Alitretinoin—Hypertension—Prednisone—psoriasis	4.3e-06	8.97e-05	CcSEcCtD
Alitretinoin—Chills—Methotrexate—psoriasis	4.29e-06	8.95e-05	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Betamethasone—psoriasis	4.25e-06	8.87e-05	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.25e-06	8.87e-05	CcSEcCtD
Alitretinoin—Pruritus—Mycophenolate mofetil—psoriasis	4.24e-06	8.85e-05	CcSEcCtD
Alitretinoin—Myalgia—Prednisone—psoriasis	4.24e-06	8.85e-05	CcSEcCtD
Alitretinoin—Arthralgia—Prednisone—psoriasis	4.24e-06	8.85e-05	CcSEcCtD
Alitretinoin—Feeling abnormal—Triamcinolone—psoriasis	4.24e-06	8.85e-05	CcSEcCtD
Alitretinoin—Anxiety—Prednisone—psoriasis	4.22e-06	8.82e-05	CcSEcCtD
Alitretinoin—Alopecia—Methotrexate—psoriasis	4.22e-06	8.82e-05	CcSEcCtD
Alitretinoin—Insomnia—Betamethasone—psoriasis	4.22e-06	8.81e-05	CcSEcCtD
Alitretinoin—Insomnia—Dexamethasone—psoriasis	4.22e-06	8.81e-05	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.21e-06	8.79e-05	CcSEcCtD
Alitretinoin—Diarrhoea—Cyclosporine—psoriasis	4.2e-06	8.78e-05	CcSEcCtD
Alitretinoin—Paraesthesia—Betamethasone—psoriasis	4.19e-06	8.75e-05	CcSEcCtD
Alitretinoin—Paraesthesia—Dexamethasone—psoriasis	4.19e-06	8.75e-05	CcSEcCtD
Alitretinoin—Discomfort—Prednisone—psoriasis	4.19e-06	8.74e-05	CcSEcCtD
Alitretinoin—Mental disorder—Methotrexate—psoriasis	4.19e-06	8.74e-05	CcSEcCtD
Alitretinoin—Malnutrition—Methotrexate—psoriasis	4.16e-06	8.69e-05	CcSEcCtD
Alitretinoin—Erythema—Methotrexate—psoriasis	4.16e-06	8.69e-05	CcSEcCtD
Alitretinoin—Hypersensitivity—Prednisolone—psoriasis	4.12e-06	8.6e-05	CcSEcCtD
Alitretinoin—Dyspepsia—Dexamethasone—psoriasis	4.11e-06	8.57e-05	CcSEcCtD
Alitretinoin—Dyspepsia—Betamethasone—psoriasis	4.11e-06	8.57e-05	CcSEcCtD
Alitretinoin—Diarrhoea—Mycophenolate mofetil—psoriasis	4.1e-06	8.56e-05	CcSEcCtD
Alitretinoin—Urticaria—Triamcinolone—psoriasis	4.08e-06	8.53e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Triamcinolone—psoriasis	4.06e-06	8.49e-05	CcSEcCtD
Alitretinoin—Dizziness—Cyclosporine—psoriasis	4.06e-06	8.48e-05	CcSEcCtD
Alitretinoin—Anaphylactic shock—Prednisone—psoriasis	4.06e-06	8.48e-05	CcSEcCtD
Alitretinoin—Oedema—Prednisone—psoriasis	4.06e-06	8.48e-05	CcSEcCtD
Alitretinoin—Decreased appetite—Dexamethasone—psoriasis	4.06e-06	8.47e-05	CcSEcCtD
Alitretinoin—Decreased appetite—Betamethasone—psoriasis	4.06e-06	8.47e-05	CcSEcCtD
Alitretinoin—Infection—Prednisone—psoriasis	4.04e-06	8.43e-05	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.03e-06	0.000292	CbGpPWpGaD
Alitretinoin—Gastrointestinal disorder—Dexamethasone—psoriasis	4.03e-06	8.41e-05	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Betamethasone—psoriasis	4.03e-06	8.41e-05	CcSEcCtD
Alitretinoin—Back pain—Methotrexate—psoriasis	4.02e-06	8.4e-05	CcSEcCtD
Alitretinoin—Hypersensitivity—Hydrocortisone—psoriasis	4.02e-06	8.4e-05	CcSEcCtD
Alitretinoin—Fatigue—Betamethasone—psoriasis	4.02e-06	8.4e-05	CcSEcCtD
Alitretinoin—Fatigue—Dexamethasone—psoriasis	4.02e-06	8.4e-05	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—NFKB1—psoriasis	4.02e-06	0.000291	CbGpPWpGaD
Alitretinoin—Shock—Prednisone—psoriasis	4e-06	8.35e-05	CcSEcCtD
Alitretinoin—Pain—Dexamethasone—psoriasis	3.99e-06	8.33e-05	CcSEcCtD
Alitretinoin—Pain—Betamethasone—psoriasis	3.99e-06	8.33e-05	CcSEcCtD
Alitretinoin—Nervous system disorder—Prednisone—psoriasis	3.98e-06	8.32e-05	CcSEcCtD
Alitretinoin—Tachycardia—Prednisone—psoriasis	3.97e-06	8.28e-05	CcSEcCtD
Alitretinoin—Dizziness—Mycophenolate mofetil—psoriasis	3.96e-06	8.28e-05	CcSEcCtD
Alitretinoin—Skin disorder—Prednisone—psoriasis	3.95e-06	8.24e-05	CcSEcCtD
Alitretinoin—Hyperhidrosis—Prednisone—psoriasis	3.93e-06	8.2e-05	CcSEcCtD
Alitretinoin—Vision blurred—Methotrexate—psoriasis	3.92e-06	8.19e-05	CcSEcCtD
Alitretinoin—Asthenia—Hydrocortisone—psoriasis	3.92e-06	8.18e-05	CcSEcCtD
Alitretinoin—Vomiting—Cyclosporine—psoriasis	3.91e-06	8.16e-05	CcSEcCtD
Alitretinoin—Rash—Cyclosporine—psoriasis	3.87e-06	8.09e-05	CcSEcCtD
Alitretinoin—Anorexia—Prednisone—psoriasis	3.87e-06	8.09e-05	CcSEcCtD
Alitretinoin—Dermatitis—Cyclosporine—psoriasis	3.87e-06	8.08e-05	CcSEcCtD
Alitretinoin—Pruritus—Hydrocortisone—psoriasis	3.86e-06	8.07e-05	CcSEcCtD
Alitretinoin—Ill-defined disorder—Methotrexate—psoriasis	3.86e-06	8.06e-05	CcSEcCtD
Alitretinoin—Headache—Cyclosporine—psoriasis	3.85e-06	8.04e-05	CcSEcCtD
Alitretinoin—Anaemia—Methotrexate—psoriasis	3.85e-06	8.03e-05	CcSEcCtD
Alitretinoin—Feeling abnormal—Betamethasone—psoriasis	3.84e-06	8.03e-05	CcSEcCtD
Alitretinoin—Feeling abnormal—Dexamethasone—psoriasis	3.84e-06	8.03e-05	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Betamethasone—psoriasis	3.81e-06	7.96e-05	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Dexamethasone—psoriasis	3.81e-06	7.96e-05	CcSEcCtD
Alitretinoin—Vomiting—Mycophenolate mofetil—psoriasis	3.81e-06	7.96e-05	CcSEcCtD
Alitretinoin—Hypersensitivity—Triamcinolone—psoriasis	3.79e-06	7.91e-05	CcSEcCtD
Alitretinoin—Rash—Mycophenolate mofetil—psoriasis	3.78e-06	7.89e-05	CcSEcCtD
Alitretinoin—Dermatitis—Mycophenolate mofetil—psoriasis	3.78e-06	7.88e-05	CcSEcCtD
Alitretinoin—Headache—Mycophenolate mofetil—psoriasis	3.75e-06	7.84e-05	CcSEcCtD
Alitretinoin—Malaise—Methotrexate—psoriasis	3.75e-06	7.83e-05	CcSEcCtD
Alitretinoin—Diarrhoea—Hydrocortisone—psoriasis	3.74e-06	7.8e-05	CcSEcCtD
Alitretinoin—Urticaria—Betamethasone—psoriasis	3.71e-06	7.74e-05	CcSEcCtD
Alitretinoin—Urticaria—Dexamethasone—psoriasis	3.71e-06	7.74e-05	CcSEcCtD
Alitretinoin—Musculoskeletal discomfort—Prednisone—psoriasis	3.7e-06	7.73e-05	CcSEcCtD
Alitretinoin—Dizziness—Prednisolone—psoriasis	3.7e-06	7.72e-05	CcSEcCtD
Alitretinoin—Asthenia—Triamcinolone—psoriasis	3.69e-06	7.7e-05	CcSEcCtD
Alitretinoin—Abdominal pain—Betamethasone—psoriasis	3.69e-06	7.7e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Dexamethasone—psoriasis	3.69e-06	7.7e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Betamethasone—psoriasis	3.69e-06	7.7e-05	CcSEcCtD
Alitretinoin—Abdominal pain—Dexamethasone—psoriasis	3.69e-06	7.7e-05	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism—CYP2S1—psoriasis	3.68e-06	0.000266	CbGpPWpGaD
Alitretinoin—Insomnia—Prednisone—psoriasis	3.67e-06	7.67e-05	CcSEcCtD
Alitretinoin—Nausea—Cyclosporine—psoriasis	3.65e-06	7.62e-05	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—VEGFA—psoriasis	3.65e-06	0.000264	CbGpPWpGaD
Alitretinoin—Paraesthesia—Prednisone—psoriasis	3.65e-06	7.62e-05	CcSEcCtD
Alitretinoin—Pruritus—Triamcinolone—psoriasis	3.64e-06	7.59e-05	CcSEcCtD
Alitretinoin—Cough—Methotrexate—psoriasis	3.63e-06	7.58e-05	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—STAT3—psoriasis	3.61e-06	0.000262	CbGpPWpGaD
Alitretinoin—Dizziness—Hydrocortisone—psoriasis	3.61e-06	7.54e-05	CcSEcCtD
Alitretinoin—Convulsion—Methotrexate—psoriasis	3.6e-06	7.53e-05	CcSEcCtD
Alitretinoin—Dyspepsia—Prednisone—psoriasis	3.58e-06	7.47e-05	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	3.57e-06	0.000259	CbGpPWpGaD
Alitretinoin—Nausea—Mycophenolate mofetil—psoriasis	3.56e-06	7.43e-05	CcSEcCtD
Alitretinoin—Myalgia—Methotrexate—psoriasis	3.54e-06	7.4e-05	CcSEcCtD
Alitretinoin—Arthralgia—Methotrexate—psoriasis	3.54e-06	7.4e-05	CcSEcCtD
Alitretinoin—Chest pain—Methotrexate—psoriasis	3.54e-06	7.4e-05	CcSEcCtD
Alitretinoin—Decreased appetite—Prednisone—psoriasis	3.53e-06	7.37e-05	CcSEcCtD
Alitretinoin—Rash—Prednisolone—psoriasis	3.53e-06	7.36e-05	CcSEcCtD
Alitretinoin—Dermatitis—Prednisolone—psoriasis	3.52e-06	7.35e-05	CcSEcCtD
Alitretinoin—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.52e-06	7.34e-05	CcSEcCtD
Alitretinoin—Fatigue—Prednisone—psoriasis	3.5e-06	7.31e-05	CcSEcCtD
Alitretinoin—Headache—Prednisolone—psoriasis	3.5e-06	7.31e-05	CcSEcCtD
Alitretinoin—Discomfort—Methotrexate—psoriasis	3.5e-06	7.31e-05	CcSEcCtD
Alitretinoin—Constipation—Prednisone—psoriasis	3.47e-06	7.25e-05	CcSEcCtD
Alitretinoin—Vomiting—Hydrocortisone—psoriasis	3.47e-06	7.25e-05	CcSEcCtD
Alitretinoin—RXRA—Metabolism—CAT—psoriasis	3.46e-06	0.000251	CbGpPWpGaD
Alitretinoin—Rash—Hydrocortisone—psoriasis	3.44e-06	7.19e-05	CcSEcCtD
Alitretinoin—Dermatitis—Hydrocortisone—psoriasis	3.44e-06	7.18e-05	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	3.44e-06	0.000249	CbGpPWpGaD
Alitretinoin—Confusional state—Methotrexate—psoriasis	3.42e-06	7.15e-05	CcSEcCtD
Alitretinoin—Headache—Hydrocortisone—psoriasis	3.42e-06	7.14e-05	CcSEcCtD
Alitretinoin—Dizziness—Triamcinolone—psoriasis	3.4e-06	7.1e-05	CcSEcCtD
Alitretinoin—Anaphylactic shock—Methotrexate—psoriasis	3.4e-06	7.09e-05	CcSEcCtD
Alitretinoin—Infection—Methotrexate—psoriasis	3.37e-06	7.04e-05	CcSEcCtD
Alitretinoin—Feeling abnormal—Prednisone—psoriasis	3.35e-06	6.99e-05	CcSEcCtD
Alitretinoin—Asthenia—Betamethasone—psoriasis	3.35e-06	6.99e-05	CcSEcCtD
Alitretinoin—Asthenia—Dexamethasone—psoriasis	3.35e-06	6.99e-05	CcSEcCtD
Alitretinoin—Nervous system disorder—Methotrexate—psoriasis	3.33e-06	6.95e-05	CcSEcCtD
Alitretinoin—Thrombocytopenia—Methotrexate—psoriasis	3.32e-06	6.94e-05	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Prednisone—psoriasis	3.32e-06	6.94e-05	CcSEcCtD
Alitretinoin—Nausea—Prednisolone—psoriasis	3.32e-06	6.93e-05	CcSEcCtD
Alitretinoin—Pruritus—Betamethasone—psoriasis	3.3e-06	6.89e-05	CcSEcCtD
Alitretinoin—Pruritus—Dexamethasone—psoriasis	3.3e-06	6.89e-05	CcSEcCtD
Alitretinoin—Skin disorder—Methotrexate—psoriasis	3.3e-06	6.89e-05	CcSEcCtD
Alitretinoin—Hyperhidrosis—Methotrexate—psoriasis	3.28e-06	6.85e-05	CcSEcCtD
Alitretinoin—Vomiting—Triamcinolone—psoriasis	3.27e-06	6.83e-05	CcSEcCtD
Alitretinoin—Nausea—Hydrocortisone—psoriasis	3.24e-06	6.77e-05	CcSEcCtD
Alitretinoin—Rash—Triamcinolone—psoriasis	3.24e-06	6.77e-05	CcSEcCtD
Alitretinoin—Dermatitis—Triamcinolone—psoriasis	3.24e-06	6.76e-05	CcSEcCtD
Alitretinoin—Anorexia—Methotrexate—psoriasis	3.24e-06	6.76e-05	CcSEcCtD
Alitretinoin—Urticaria—Prednisone—psoriasis	3.23e-06	6.74e-05	CcSEcCtD
Alitretinoin—Headache—Triamcinolone—psoriasis	3.22e-06	6.72e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Prednisone—psoriasis	3.21e-06	6.71e-05	CcSEcCtD
Alitretinoin—Abdominal pain—Prednisone—psoriasis	3.21e-06	6.71e-05	CcSEcCtD
Alitretinoin—Diarrhoea—Dexamethasone—psoriasis	3.19e-06	6.66e-05	CcSEcCtD
Alitretinoin—Diarrhoea—Betamethasone—psoriasis	3.19e-06	6.66e-05	CcSEcCtD
Alitretinoin—Hypotension—Methotrexate—psoriasis	3.17e-06	6.62e-05	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—TNF—psoriasis	3.13e-06	0.000226	CbGpPWpGaD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.12e-06	0.000226	CbGpPWpGaD
Alitretinoin—Musculoskeletal discomfort—Methotrexate—psoriasis	3.09e-06	6.46e-05	CcSEcCtD
Alitretinoin—Dizziness—Dexamethasone—psoriasis	3.09e-06	6.44e-05	CcSEcCtD
Alitretinoin—Dizziness—Betamethasone—psoriasis	3.09e-06	6.44e-05	CcSEcCtD
Alitretinoin—Insomnia—Methotrexate—psoriasis	3.07e-06	6.41e-05	CcSEcCtD
Alitretinoin—Nausea—Triamcinolone—psoriasis	3.05e-06	6.38e-05	CcSEcCtD
Alitretinoin—Paraesthesia—Methotrexate—psoriasis	3.05e-06	6.37e-05	CcSEcCtD
Alitretinoin—Dyspnoea—Methotrexate—psoriasis	3.03e-06	6.32e-05	CcSEcCtD
Alitretinoin—Somnolence—Methotrexate—psoriasis	3.02e-06	6.3e-05	CcSEcCtD
Alitretinoin—RXRA—Gene Expression—PPARG—psoriasis	3.01e-06	0.000218	CbGpPWpGaD
Alitretinoin—Hypersensitivity—Prednisone—psoriasis	2.99e-06	6.25e-05	CcSEcCtD
Alitretinoin—Dyspepsia—Methotrexate—psoriasis	2.99e-06	6.24e-05	CcSEcCtD
Alitretinoin—Vomiting—Betamethasone—psoriasis	2.97e-06	6.19e-05	CcSEcCtD
Alitretinoin—Vomiting—Dexamethasone—psoriasis	2.97e-06	6.19e-05	CcSEcCtD
Alitretinoin—Decreased appetite—Methotrexate—psoriasis	2.95e-06	6.16e-05	CcSEcCtD
Alitretinoin—Rash—Betamethasone—psoriasis	2.94e-06	6.14e-05	CcSEcCtD
Alitretinoin—Rash—Dexamethasone—psoriasis	2.94e-06	6.14e-05	CcSEcCtD
Alitretinoin—Dermatitis—Dexamethasone—psoriasis	2.94e-06	6.14e-05	CcSEcCtD
Alitretinoin—Dermatitis—Betamethasone—psoriasis	2.94e-06	6.14e-05	CcSEcCtD
Alitretinoin—Gastrointestinal disorder—Methotrexate—psoriasis	2.93e-06	6.12e-05	CcSEcCtD
Alitretinoin—Fatigue—Methotrexate—psoriasis	2.93e-06	6.11e-05	CcSEcCtD
Alitretinoin—Headache—Betamethasone—psoriasis	2.92e-06	6.1e-05	CcSEcCtD
Alitretinoin—Headache—Dexamethasone—psoriasis	2.92e-06	6.1e-05	CcSEcCtD
Alitretinoin—Asthenia—Prednisone—psoriasis	2.91e-06	6.09e-05	CcSEcCtD
Alitretinoin—Pain—Methotrexate—psoriasis	2.9e-06	6.06e-05	CcSEcCtD
Alitretinoin—Pruritus—Prednisone—psoriasis	2.87e-06	6e-05	CcSEcCtD
Alitretinoin—Feeling abnormal—Methotrexate—psoriasis	2.8e-06	5.84e-05	CcSEcCtD
Alitretinoin—Diarrhoea—Prednisone—psoriasis	2.78e-06	5.8e-05	CcSEcCtD
Alitretinoin—Gastrointestinal pain—Methotrexate—psoriasis	2.78e-06	5.8e-05	CcSEcCtD
Alitretinoin—Nausea—Betamethasone—psoriasis	2.77e-06	5.79e-05	CcSEcCtD
Alitretinoin—Nausea—Dexamethasone—psoriasis	2.77e-06	5.79e-05	CcSEcCtD
Alitretinoin—Urticaria—Methotrexate—psoriasis	2.7e-06	5.63e-05	CcSEcCtD
Alitretinoin—RXRA—Metabolism—APOE—psoriasis	2.69e-06	0.000195	CbGpPWpGaD
Alitretinoin—Dizziness—Prednisone—psoriasis	2.69e-06	5.61e-05	CcSEcCtD
Alitretinoin—Body temperature increased—Methotrexate—psoriasis	2.68e-06	5.6e-05	CcSEcCtD
Alitretinoin—Abdominal pain—Methotrexate—psoriasis	2.68e-06	5.6e-05	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.67e-06	0.000194	CbGpPWpGaD
Alitretinoin—Vomiting—Prednisone—psoriasis	2.58e-06	5.39e-05	CcSEcCtD
Alitretinoin—Rash—Prednisone—psoriasis	2.56e-06	5.35e-05	CcSEcCtD
Alitretinoin—Dermatitis—Prednisone—psoriasis	2.56e-06	5.34e-05	CcSEcCtD
Alitretinoin—Headache—Prednisone—psoriasis	2.55e-06	5.31e-05	CcSEcCtD
Alitretinoin—RXRA—Developmental Biology—IL6—psoriasis	2.52e-06	0.000183	CbGpPWpGaD
Alitretinoin—Hypersensitivity—Methotrexate—psoriasis	2.5e-06	5.22e-05	CcSEcCtD
Alitretinoin—Asthenia—Methotrexate—psoriasis	2.44e-06	5.09e-05	CcSEcCtD
Alitretinoin—Nausea—Prednisone—psoriasis	2.41e-06	5.04e-05	CcSEcCtD
Alitretinoin—Pruritus—Methotrexate—psoriasis	2.4e-06	5.02e-05	CcSEcCtD
Alitretinoin—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.36e-06	0.000171	CbGpPWpGaD
Alitretinoin—RXRA—Metabolism—PPARG—psoriasis	2.34e-06	0.00017	CbGpPWpGaD
Alitretinoin—Diarrhoea—Methotrexate—psoriasis	2.32e-06	4.85e-05	CcSEcCtD
Alitretinoin—ABCB1—Metabolism—CARM1—psoriasis	2.25e-06	0.000163	CbGpPWpGaD
Alitretinoin—Dizziness—Methotrexate—psoriasis	2.25e-06	4.69e-05	CcSEcCtD
Alitretinoin—Vomiting—Methotrexate—psoriasis	2.16e-06	4.51e-05	CcSEcCtD
Alitretinoin—Rash—Methotrexate—psoriasis	2.14e-06	4.47e-05	CcSEcCtD
Alitretinoin—Dermatitis—Methotrexate—psoriasis	2.14e-06	4.47e-05	CcSEcCtD
Alitretinoin—Headache—Methotrexate—psoriasis	2.13e-06	4.44e-05	CcSEcCtD
Alitretinoin—Nausea—Methotrexate—psoriasis	2.02e-06	4.21e-05	CcSEcCtD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.93e-06	0.000139	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CARM1—psoriasis	1.79e-06	0.00013	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.68e-06	0.000122	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—CAT—psoriasis	1.38e-06	0.0001	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—CAT—psoriasis	1.1e-06	8e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—APOE—psoriasis	1.07e-06	7.78e-05	CbGpPWpGaD
Alitretinoin—ABCB1—Metabolism—PPARG—psoriasis	9.36e-07	6.78e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—APOE—psoriasis	8.58e-07	6.21e-05	CbGpPWpGaD
Alitretinoin—CYP1A2—Metabolism—PPARG—psoriasis	7.47e-07	5.41e-05	CbGpPWpGaD
